Barton-Maclaren T S, Wade M, Basu N, Bayen S, Grundy J, Marlatt V, Moore R, Parent L, Parrott J, Grigorova P, Pinsonnault-Cooper J, Langlois V S
Existing Substances Risk Assessment Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Canada.
Environmental Health Centre, Environmental Health, Science and Research Bureau, Health Canada, Ottawa, ON, Canada.
Environ Res. 2022 Mar;204(Pt C):112225. doi: 10.1016/j.envres.2021.112225. Epub 2021 Oct 16.
Globally, regulatory authorities grapple with the challenge of assessing the hazards and risks to human and ecosystem health that may result from exposure to chemicals that disrupt the normal functioning of endocrine systems. Rapidly increasing number of chemicals in commerce, coupled with the reliance on traditional, costly animal experiments for hazard characterization - often with limited sensitivity to many important mechanisms of endocrine disruption -, presents ongoing challenges for chemical regulation. The consequence is a limited number of chemicals for which there is sufficient data to assess if there is endocrine toxicity and hence few chemicals with thorough hazard characterization. To address this challenge, regulatory assessment of endocrine disrupting chemicals (EDCs) is benefiting from a revolution in toxicology that focuses on New Approach Methodologies (NAMs) to more rapidly identify, prioritize, and assess the potential risks from exposure to chemicals using novel, more efficient, and more mechanistically driven methodologies and tools. Incorporated into Integrated Approaches to Testing and Assessment (IATA) and guided by conceptual frameworks such as Adverse Outcome Pathways (AOPs), emerging approaches focus initially on molecular interactions between the test chemical and potentially vulnerable biological systems instead of the need for animal toxicity data. These new toxicity testing methods can be complemented with in silico and computational toxicology approaches, including those that predict chemical kinetics. Coupled with exposure data, these will inform risk-based decision-making approaches. Canada is part of a global network collaborating on building confidence in the use of NAMs for regulatory assessment of EDCs. Herein, we review the current approaches to EDC regulation globally (mainly from the perspective of human health), and provide a perspective on how the advances for regulatory testing and assessment can be applied and discuss the promises and challenges faced in adopting these novel approaches to minimize risks due to EDC exposure in Canada, and our world.
在全球范围内,监管机构面临着一项挑战,即评估接触那些会干扰内分泌系统正常功能的化学物质可能对人类和生态系统健康造成的危害和风险。商业领域中化学物质的数量迅速增加,再加上依靠传统且成本高昂的动物实验来进行危害特征描述——而这些实验对许多重要的内分泌干扰机制往往敏感度有限——这给化学物质监管带来了持续的挑战。结果是,仅有有限数量的化学物质有足够数据来评估其是否具有内分泌毒性,因此,经过全面危害特征描述的化学物质很少。为应对这一挑战,内分泌干扰化学物质(EDC)的监管评估正受益于毒理学领域的一场变革,这场变革聚焦于新方法学(NAMs),即使用新颖、更高效且更具机制驱动性的方法和工具,更快速地识别、确定优先次序并评估接触化学物质所带来的潜在风险。这些新兴方法被纳入综合测试与评估方法(IATA),并以诸如不良结局途径(AOPs)等概念框架为指导,最初聚焦于测试化学物质与潜在易损生物系统之间的分子相互作用,而非对动物毒性数据的需求。这些新的毒性测试方法可以通过计算机模拟和计算毒理学方法加以补充,包括那些预测化学动力学的方法。再结合接触数据,这些将为基于风险的决策方法提供信息。加拿大是一个全球网络的一部分,该网络致力于在将新方法学用于EDC监管评估方面建立信心。在此,我们回顾全球范围内(主要从人类健康角度)当前对EDC的监管方法,并就如何应用监管测试与评估方面的进展提供观点,同时讨论在加拿大乃至全球采用这些新方法以尽量减少因接触EDC而产生的风险时所面临的前景与挑战。